Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting

Protein degraders, emerging as a novel class of therapeutic agents, have gained widespread attention due to their advantages. They have several advantages over traditional small molecule inhibitors, including ...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Correspondence Source Type: research